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A fast, accurate, and ultrasensitive high-performance liquid chromatography 
method with chemiluminescence detection (HPLC-CL) was optimized and validated for 
the determination of pyrroloquinoline quinone (PQQ) concentration in human plasma 
following solid-phase extraction (SPE). This method is based on the redox cycle of the 
reaction between PQQ and dithiothreitol, which generates reactive oxygen species that 
can be detected using luminol as a CL probe. The isocratic HPLC system comprised an 
ODS column and 4.0 mM tetra-n-butylammonium bromide in Tris-HNO3 buffer (pH 
8.8; 50 mM)-acetonitrile (7:3, v/v) as mobile phase. A novel, rapid, and simple SPE 
method was also developed providing excellent %recovery (≥95.2%) for PQQ from 
human plasma samples. The proposed method was linear over the range of 4.0–400 
nmol/L plasma of PQQ with a lower detection limit (S/N = 3) of 1.08 nmol/L plasma 
(0.27 nM). The method was successfully implemented to determine PQQ concentration 
in the plasma of healthy individuals after administration of PQQ supplements. 
 






Pyrroloquinoline quinone (PQQ, 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-
f]quinoline-2,7,9-tricarboxylic acid) is a cofactor for methanol dehydrogenase [1] and is 
categorized as a member of the vitamin B family [2]. PQQ plays important roles in 
mammals, including protection against liver [3], heart [4], and brain injuries [5], 
enhancement of the synthesis of DNA in human fibroblasts [6], and promotion of the 
production of the nerve growth factor [7]. In addition, it has a defensive effect against 
embryonic cataract induced by hydrocortisone [8] and acts as a radical scavenger [9, 
10]. It also inhibits the formation of amyloid fibrils and protects from the toxicity of C-
truncated alpha-synuclein variants, which are properties that make it an effective agent 
in the prevention of Parkinson’s disease [11, 12]. Finally, it prevents cognitive 
deficiency in oxidative-stress-induced neurodegeneration [13], and its disodium salt is 
used as a dietary supplement. Considering the many physiological roles and activities of 
this compound, a highly sensitive analytical method for the determination of PQQ 
concentration in human plasma is required. 
A number of methods have been reported for PQQ determination in different 
matrices. An HPLC-ESI-MS/MS-based method [14] and a GC-MS-based method 
(involving the preliminary derivatization of PQQ with phenyl trimethylammonium 
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hydroxide) [15] were utilized for the quantitative analysis of PQQ in various foods. 
Quantitative CE-UV [16] and HPLC-ECD [17], in addition to an HPLC-UV and cyclic 
voltammetry qualitative [18] approach, were implemented for the determination of PQQ 
standard. PQQ was also determined in different pig and bovine enzymes by HPLC-UV 
and mass spectrometry (MS) detection after PQQ conversion to a hydrazone derivative 
[19]. None of these methods [14–21] were applied to human plasma; in addition, many 
of them depended on the use of sophisticated instruments [14, 15, 17] and involved 
tedious and time-consuming derivatization procedures [15, 19]. Gas 
chromatography-MS (GC-MS [22]) has been the only bioanalytical method for PQQ 
concentration determination reported so far. However, the derivatization procedure with 
phenyltrimethylammonium hydroxide that this protocol involved required harsh 
conditions such as heating at 100°C for 15 min. The high cost and complexity of 
conducting MS experiments limit the widespread use of this method, which suffers from 
additional drawbacks such as a multi-step, lengthy, and complicated extraction 
procedure (Table 1). Therefore, developing a simple, sensitive, rapid, and convenient 
analytical method for the analysis of PQQ level in human plasma remains a very 




It has been reported that PQQ is present in human plasma at very low 
concentration [22, 23]. Hence, developing a reliable and efficient sample preparation 
approach and a subsequent sensitive analytical method to determine plasma PQQ level 
constitute an analytical challenge. Among the various detection methods, 
chemiluminescence (CL) detection provides high sensitivity that enables the 
determination of trace amounts of many species using a simple instrument. However, to 
date, no method relying on CL detection has been applied to the determination of PQQ 
concentration. Our research group reported a CL assay for the determination of quinone 
concentration that utilizes quinone characteristic redox reaction cycle [24–26]. In this 
approach, quinones are reduced by dithiothreitol (DTT) to yield the corresponding 
semiquinone radicals, which convert dissolved oxygen to the superoxide anion radical, 
which will, in turn, produce CL upon reaction with luminol (Fig. 1). The aim of the 
present study is to employ this redox cycle to develop an ultra-sensitive, simple, rapid, 
and convenient HPLC-CL detection method for the determination of PQQ concentration 
in human plasma. 
Sample preparation is a very important step in the analysis of PQQ in plasma. 
Only one sample preparation procedure, which combines two liquid–liquid and one 
solid–phase extraction (SPE) steps, has been reported [22, 27] for the extraction of PQQ 
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from plasma. Due to the complication and time-consuming nature of this extraction 
method [22, 27], it was necessary to develop an alternative rapid, efficient, simple, and 
selective procedure for the extraction of PQQ from plasma. Hence, it was also one of 
our main targets to develop an efficient SPE procedure for extracting PQQ and then to 
couple it with the HPLC-CL detection for monitoring trace amounts of PQQ in plasma. 
The conditions and relevant parameters of the extraction of PQQ by SPE were carefully 
optimized, and the analytical performance of the method was evaluated. 
Finally, this method was applied to the quantification of PQQ in human plasma. 
For this purpose, we collected plasma samples from healthy individuals who had taken 
PQQ supplements and studied how PQQ plasma concentration changed over time. 
 
2. Experimental 
2.1. Materials and reagents 
All chemicals were of extra-pure analytical grade and solvents were of HPLC 
grade. PQQ disodium salt was sourced from Mitsubishi Gas Chemical Co. Inc. (Tokyo, 
Japan). Acetonitrile (ACN), methanol, and nitric acid were supplied by Kanto Chemical 
Co. (Tokyo, Japan). DTT and hydrochloric acid were sourced from Nacalai Tesque 
(Kyoto, Japan). Luminol and sodium dihydrogen phosphate were sourced from Wako 
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Pure Chemical Industries, Ltd. (Osaka, Japan). Tris (hydroxymethyl) aminomethane 
(Tris) was obtained from MP Biomedicals Co. (Santa Ana, USA). 
Tetra-n-butylammonium bromide (TBAB) was sourced from Tokyo Chemical Industries 
(Tokyo, Japan). Sodium hydroxide was purchased from Merck Co. (Darmstadt, 
Germany). Pyridine was sourced from Kishida Chemicals (Osaka, Japan). PQQ stock 
solutions (25 µM) were prepared in water and kept in a refrigerator at 4°C. Tris-HNO3 
buffer (50 mM) was prepared in water and its pH was adjusted to 8.8; subsequently, a 
4.0 mM solution of TBAB was prepared in this buffer. DTT (0.15 mM) and luminol (1.5 
mM) solutions were prepared fresh in ACN and NaOHaq (150 mM), respectively. 
 
2.2. Instrumentation 
The HPLC system (Fig. 2) consisted of three Shimadzu LC-20A pumps (Kyoto, 
Japan), a Rheodyne injector (Cotati, CA, USA) with a loop size of 20 µL, a CLD-10A 
CL detector (Shimadzu), and an EZ Chrom Elite chromatography data acquisition 
system (Scientific software, Pleasanton, CA, USA). PTFE tubing (7 m × 0.5 mm i.d., 





2.3. HPLC conditions 
Chromatographic separation was performed on an InertSustain C18 (150 × 4.6 
mm i.d., 3 µm particle size, GL Sciences, Tokyo) column. An InertSustain C18 cartridge 
guard column E (10 × 4.0 mm i.d., 3 µm, GL Sciences) was used. Isocratic elution was 
accomplished with a mixture of TBAB (4.0 mM) in Tris-HNO3 buffer (pH 8.8; 50 
mM)-ACN (7:3, v/v) at a flow rate of 1.0 mL/min. TBAB was utilized because it can 
form ion pair with PQQ and cause PQQ to be retained on a hydrophobic analytical 
column. The eluent from the column was mixed simultaneously with DTT (0.15 mM) 
and luminol (1.5 mM) solutions and then passed to the reaction coil. DTT and luminol 
solutions flow rates were set at 0.25 mL/min. 
 
2.4. Calibration curve 
Standard PQQ solutions were prepared in the 1–250 nM concentration range by 
diluting the PQQ stock solution (25 μM) with the mobile phase. A blank experiment 
was carried out simultaneously. The average peak areas were plotted versus the 




2.5. Plasma samples 
Plasma samples were collected from six healthy individuals (two males and four 
females, mean age 25.8 ± 7.0 years). In order to investigate the variation of PQQ 
concentration in plasma after the oral administration of this chemical as a supplement, 
PQQ disodium salt supplement capsules (100 mg, BioPQQ, Mitsubishi Gas Chemical 
Co. Inc.) were administered to the healthy individuals once a day for 7 days. Each 
capsule was made of cellulose and contained Bio PQQ (10 mg), starch (150.5 mg), 
starch hydrolysate (82 mg), and calcium stearate (7.5 mg) [28]. Capsule stability was 
confirmed through a dissolution test performed according to the pharmacopoeia. On the 
1st day, whole-blood samples were collected before (0 h) administration of PQQ and 
then after 3 and 24 h. After daily administration of the supplement for 6 days, on the 7th 
day, whole-blood samples were collected before (0 h) administration of the PQQ 
supplement and after 3 h. The blood samples were collected in blood-sampling tubes 
containing EDTA as an anticoagulant. After centrifuging at 3000 rpm for 10 min at 5°C, 
the supernatant was collected and stored at −80°C until analysis. This experiment was 
performed according to the guidelines of the Ethics Committee of the School of 




2.6. SPE procedure and determination of PQQ concentration in plasma 
SPE was performed using a Varian Bond Elut C18 cartridge (500 mg/3 mL) 
supplied by Agilent Technologies (CA, USA). Aliquots of 200 µL of the plasma samples 
collected as described in section 2.5 or pooled plasma samples spiked with PQQ were 
pipetted into 1.5 mL tubes and acidified with 200 µL of 1 M NaH2PO4 /HCl (pH 2.0), 
and the tubes were subsequently vortexed for 1 min. The conditioning and equilibration 
of the C18 cartridge were carried out using 4 mL of methanol and 4 mL of purified 
water, respectively. A 300 µL aliquot of each acidified plasma sample was then loaded 
onto the cartridge. The cartridge was washed sequentially with 2 mL of purified water 
and 600 µL of 5% aqueous pyridine. Finally, the elution was carried out with 600 µL of 
30% ACN, a 20 µL aliquot was injected into the HPLC system. The sample was diluted 
by SPE, and the final concentration of PQQ was 1/4 that of the original plasma sample. 
 
2.7. Method validation 
Method validation was performed according to FDA guidelines for the validation 
of bioanalytical [29] methods. The calibration curve (drawn on the basis of 8 points) 
was performed by measuring the PQQ concentration of plasma samples spiked with a 
PQQ standard covering the range of 4–400 nmol/L plasma. The limit of detection 
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(LOD) was determined at a signal-to-noise (S/N) ratio of 3. 
The accuracy and precision of the method were determined by analysis of spiked 
human plasma at three concentration levels using five replicates for each concentration. 
The intra-day precision of the proposed method was assessed at low (4 nmol/L plasma), 
medium (40 nmol/L plasma), and high (200 nmol/L plasma) plasma concentration level 
using five determinations per sample on the same day. Inter-day precision was assessed 
by determining PQQ levels at the same three concentrations for five consecutive days. 
The values of %RSD for the five determinations express the precision of the method. 
Furthermore, the stability of PQQ in plasma was studied at concentrations of 20 
and 200 nmol/L plasma. Short- and long-term stabilities of PQQ in plasma were 
evaluated after letting samples stand at room temperature for 1, 4, and 24 h. In addition, 
the stability of PQQ in plasma with respect to freeze–thaw cycles was determined. The 
plasma samples spiked with PQQ were stored at −80°C and subsequently thawed to 
room temperature, and this process was repeated a total of three times. In addition, the 
plasma samples stored at −80°C for 7 days were also measured. 
 
3. Results and Discussion 
3.1. Optimization of the HPLC-CL conditions 
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To improve the sensitivity of the analytical approach, CL reaction conditions were 
optimized. The influences of different variables on the peak area and S/N ratio were 
investigated using a standard solution of PQQ. Previous studies [24–26] provided 
evidence that the CL generated increases steadily upon mixing quinone with DTT and 
luminol. Therefore, it is better to have the mixed solution pass through a reaction coil 
before measuring CL intensity. The effect of the length of the reaction coil was studied 
over the 6–8 m range in a coil with a constant internal diameter of 0.5 mm (Fig. 3a). 
The maximum peak area was obtained with a coil measuring 6 m, but the S/N ratio 
increased up to a coil length of 7 m and then decreased. Therefore, a reaction coil with a 
length of 7 m was selected as the optimum. The effects of the concentrations of the 
reagents were also examined. The influence of luminol was studied over a 0.5–3.0 mM 
range. The peak area and S/N ratio increased up to a 1.5 mM concentration and then 
decreased (Fig. 3b). Hence, 1.5 mM luminol was chosen as the optimum concentration. 
The effect of NaOH concentration was also studied over a 50–300 mM range. The 
highest peak area and S/N ratio were observed for a 150 mM solution of NaOH (Fig. 
3c). The concentration of DTT was studied in the 0.05–0.4 mM range. The maximum 
peak area was observed at 0.1 mM concentration, whereas the maximum S/N ratio was 
observed at 0.15 mM concentration (Fig. 3d), so 0.15 mM DTT was selected as the 
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optimum concentration for conducting the experiment. Fig. 4a shows a typical 
chromatogram of a standard solution of 50 nM PQQ obtained by implementing the 
proposed method. The peak derived from PQQ was detected at 10.7 min. 
 
3.2. Method linearity 
The calibration curve of the method was constructed by plotting the average peak 
area of triplicate analyses versus the known PQQ concentration of standard solutions in 
the 1–250 nM range. The regression equation utilized was Y = (13.0 ± 1.0) × 104 X - 
(13.3 ± 11.9) × 104, where Y is the peak area and X is the concentration of PQQ (nM). 
The detection limit of PQQ was 0.23 nM (4.6 fmol/injection) at S/N = 3. 
 
3.3. Optimization of the extraction method 
The HPLC-CL method thus developed displayed enough sensitivity to be utilized 
in the determination of PQQ concentration in human plasma. We then investigated the 
performance of the method for the extraction of PQQ from plasma samples. Suzuki et al. 
[27] investigated the conditions for extracting PQQ from biological samples 
implementing an approach comprising of a liquid–liquid extraction followed by a 
solid-phase extraction. In this method, the PQQ present in a biological sample was 
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extracted into an organic layer then re-extracted into an aqueous layer. After the second 
extraction, HCl was added to the aqueous layer to acidify the sample, and PQQ was 
extracted using a C18 cartridge; the recovery rate at this point was 50–105%. This 
procedure has been implemented in the method for the determination of PQQ 
concentration in biological samples by GC-MS reported by Kumazawa et al [22]. This 
extraction procedure is time-consuming because it involves two extraction modes to be 
implemented consecutively. Therefore, we set out to develop a fast and convenient 
extraction method to trace the amount of PQQ in human plasma. We studied the 
deproteinization method using an organic solvent and a liquid–liquid extraction method 
using ethyl acetate, but in neither case were we able to achieve a sufficient recovery rate. 
Therefore, the SPE method using the C18 cartridge, which is the most commonly used 
solid phase relying on hydrophobic interactions, was examined. The solvent to be used 
in SPE was determined on the basis of a report by Suzuki et al [27]. We tried many 
washing solvents, including water, ACN, aqueous ACN (10–50%), and aqueous 
pyridine (2–10%) alone or in combination with each other, with the washing step being 
followed by elution with different mobile phases: 30% aqueous ACN, water, or 5% 
aqueous pyridine. We obtained the best results using water followed by 5% aqueous 
pyridine for the washing step and 30% aqueous ACN as eluting solvent, as mentioned in 
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section 2.6. The SPE procedure developed required a smaller sample volume than that 
needed in the reported method, and it involves a simple operation. Additionally, 30% 
aqueous ACN was used as eluent instead of 5% aqueous pyridine, which allowed direct 
injection of the eluate into the HPLC-CL system without the need for evaporation and 
reconstitution steps. Furthermore, this method showed high selectivity for PQQ, with no 
evidence of interference by plasma components in the detection of PQQ. In fact, in our 
method, PQQ concentration was measured using the reactive oxygen species generated 
by the redox cycle of quinone, so endogenous quinones, including vitamin K 
homologues and coenzyme Q10, could theoretically interfere with the measurement of 
PQQ level. As anticipated, however, such endogenous biological components were 
removed by the SPE method we hereby propose. 
 
3.4. Method validation with plasma 
The method was applied to the determination of PQQ concentration in human 
plasma. PQQ was selectively extracted by SPE from plasma samples spiked with a PQQ 
standard solution and the analyte was subsequently detected. The plasma components 
did not affect the detection of PQQ (Figs. 4b and 4c). The calibration curve for the 
analysis was drawn using human pooled plasma that had been spiked with PQQ over 
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the range of 4–400 nmol/L plasma. The regression equation of the calibration curve was 
Y = (2.7 ± 0.2) × 104 X + (4.3 ± 2.9) × 104, where Y is the peak area and X is the 
concentration of PQQ (nM) and the LOD of was 0.27 nM (5.4 fmol/injection). The 
LOQ was found to be 1.0 nM (4.0 nmol/L plasma) with good accuracy (%found > 95%) 
and acceptable precision (%RSD ≤ 5.6%) that are in good agreement with the FDA 
validation guidelines [29]. The small increase in background luminescence was the 
result of the presence of reactive oxygen species or other components in plasma. 
However, the LOD of standard and human plasma sample calculated by S/N ratio 
showed only a limited change. The intra- and inter-day accuracy and precision of the 
method were determined by the analysis of plasma samples spiked with PQQ at three 
concentrations (4, 40, and 200 nmol/L plasma). For all samples, the accuracy was in the 
95.2–100.3% range and the %RSD for intra- and inter-day precision did not exceed 
6.1% (Table 2). These results indicated the high reproducibility of this method. 
The stability of PQQ in plasma was examined using plasma samples spiked 
with PQQ at concentrations of 20 and 200 nmol/L plasma and determining (i) 
short-term stability at room temperature for 1 h and 4 h, (ii) long-term stability for 24 h 
at room temperature, (iii) stability after three freeze–thaw cycles, and (iv) stability of a 
frozen sample kept at −80°C for 7 days. In particular, the stability of the PQQ in the 
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plasma samples treated as mentioned above was determined by comparing with freshly 
prepared one. The recovery rate of PQQ in all samples was ≧81.8% under the studied 
conditions, and the stability of PQQ in plasma was confirmed (Table 3). 
 
3.5. Variations of PQQ concentration in plasma after administration of PQQ 
supplements 
The developed HPLC-CL method was applied to the determination of PQQ 
concentration in human plasma after continuous administration of PQQ supplements. 
Typical chromatograms of human plasma at (a) 0 h (before administration), (b) 3 h, and 
(c) 24 h after administration of PQQ on the 1st day of the experiment are reported in 
Figs. 5a, 5b, and 5c, respectively. PQQ concentrations in plasma are also depicted in Fig. 
6a. As shown in these figures, PQQ was not detected in plasma before administration of 
PQQ supplements. On the other hand, PQQ was detected in the plasma of all 
individuals in the range of 16.4–53.8 nmol/L plasma after 3 h of administration. 
Although PQQ was also detected in plasma after 24 h of administration, the 
concentrations of PQQ were greatly reduced at this stage compared to those of the 
samples collected after 3 h of administration. After continuous administration for 6 days, 
significant concentrations of PQQ were detected in the plasma samples even before the 
administration of supplements. In addition, PQQ concentrations after 3 h of 
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administration on the 7th day of the experiment were higher (Fig. 6b) than their 
counterparts determined on the 1st day. These results suggested that the continuous 
administration of PQQ supplements could increase the basal blood concentration of 
PQQ. The values of PQQ concentration in plasma were summarized in Table S1 
(supporting file). Also, it is noteworthy that there is a large variance in PQQ 
concentration among volunteers (%RSD reached 62.1%) which is also reported by 
Harris et al. [23] with %RSD of about 70.3%. This could be due to individual variation 
in metabolism of PQQ. 
 
4. Conclusion 
This study is the first report on the use of an HPLC-CL system for the 
determination of PQQ concentration in plasma. The developed method relies on CL 
detection of 3-aminophthalate produced by the reaction of PQQ with DTT and luminol. 
A novel, rapid, and simple SPE procedure was also developed and coupled to the 
proposed HPLC-CL method for ultrasensitive determination of PQQ concentration in 
human plasma samples without any matrix interference. In addition, it was possible to 
detect PQQ in plasma samples from individuals who had taken PQQ supplements. 
Hence, the developed method is suitable for the determination of plasma concentration 
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of PQQ to study the pharmacokinetics of this compound. In addition, the method can be 
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Table 1 Critical comparison of the performance of the proposed and reported methods 














No reaction 30-40 Foods (1.5) 
- High LOQ (150 
fmol/injection) 














- Tedious extraction 
- Sophisticated and 
expensive instruments 
- Harsh reaction condition 
[15] 
[22] 




7000 Poor sensitivity [16] 
HPLC-ECD No reaction N/A* 
Standard 
solution 




No reaction N/A* 
Standard 
solution 

































100 Low sensitivity [21] 
HPLC-CL 







- Automated online 
reaction 
- High sensitivity 
 
  




Table 2 Accuracy and precision of the proposed method for the determination of PQQ 
concentration in PQQ-spiked human plasma samples. 
 








Intra-day (n = 5)    
 4  4.01 100.3 5.5 
40  38.9  97.3 1.6 
200 193.6  96.8 6.1 
Inter-day (n = 5)    
 4  3.81  95.2 5.6 
40  39.0  97.5 1.9 
200 194.8  97.3 3.3 








20 nmol/L plasma 200 nmol/L plasma 
Room temperature (1 h) 104.4 100.2 
Room temperature (4 h)  95.7  99.5 
Room temperature (24 h)  81.8  98.5 
Three freeze–thaw cycles (–80 °C)  98.0  87.7 







































1.0 mL/min 0.25 mL/min 0.25 mL/min









Fig. 3 Effects of reaction coil length and different reagent concentrations on the relative 
peak area and S/N ratio in CL measurements of samples containing PQQ at 50 nM 
concentration. Effect on peak area and S/N ratio of (a) reaction coil length, (b) luminol 













































































































































Fig. 4 Chromatograms of (a) standard 50 nM solution of PQQ, (b) blank human plasma, 








































Fig. 5 Chromatograms of human plasma samples collected (a) before, (b) after 3 h, and 








































Fig. 6 PQQ concentrations in plasma samples collected from six individuals on (a) the 
1st and (b) 7th day of the experiment. Each bar shows the PQQ concentration in 
individuals’ plasma at each blood sampling and n.d. means not detected. * Indicates that 







































































Table S1. PQQ concentrations in plasma samples collected from six individuals on the 
1st and 7th day of the experiment. 
 
Experiment day Time Range  
(nmol/L plasma, n = 6) 
Mean ± SEM***  
(nmol/L plasma, n = 6) 
1st day 0 h n.d.* n.d.* 
3 h 16.4–53.8 25.4 ± 5.9 
24 h n.d.*–9.8 7.0 ± 1.7 
7th day 0 h Trace**–25.6 14.0 ± 4.4 
3 h 23.0–83.5 48.0 ± 8.6 
* n.d. means not detected 
** Trace means that the value lies between LOD and LOQ 
*** SEM is the standard error of mean. 
